Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00123955 · ClinicalTrials.gov registry record · Phase 3

PIE II: Pharmacological Intervention in the Elderly II

A Phase 3 study of Heart Failure, Congestive and Diastolic Heart Failure, sponsored by Wake Forest University.

Completed
Registry status
Phase 3
Development phase
80
Enrollment target
1
Study location

NCT00123955 is a Phase 3 study of Heart Failure, Congestive and Diastolic Heart Failure that has completed, run by Wake Forest University. The registered enrollment target is 80 participants, below the 640-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00123955, a Phase 3 study of Heart Failure, Congestive and Diastolic Heart Failure, has completed, sponsored by Wake Forest University.

COMPLETED
Registry status
Phase 3
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).

Interventions

  • DRUG Placebo
  • DRUG Spironolactone

Study Locations (1)

North Carolina

  • Wake Forest University Baptist Medical Center - Winston-Salem

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2005-04
Est. Completion 2012-12
Phase Phase 3

Sponsor

Wake Forest University

100 total trials

What the Registry Record Tells You About NCT00123955

The ClinicalTrials.gov registry entry for NCT00123955 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 640-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (87% lower). The listed sponsor is Wake Forest University, which has 100 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure, Congestive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00123955 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.

Frequently Asked Questions

What is clinical trial NCT00123955 about?

NCT00123955 is a clinical study titled "PIE II: Pharmacological Intervention in the Elderly II". The purpose of this study is to examine whether spironolactone will improve exercise tolerance and quality of life in elderly patients with heart failure preserved ejection fraction (HFPEF).

What is the current status of trial NCT00123955?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2005-04. Estimated completion is 2012-12.

What conditions does trial NCT00123955 study?

This clinical trial studies the following conditions: Heart Failure, Congestive, Diastolic Heart Failure.

What interventions are being tested in trial NCT00123955?

The interventions under investigation include: Placebo (DRUG), Spironolactone (DRUG).

Who is sponsoring clinical trial NCT00123955?

This trial is sponsored by Wake Forest University, which has 100 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00123955 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.